OS, which was the primary endpoint of the study, was also significantly longer with nivolumab plus ipilimumab than with chemotherapy, among patients with tumour cell PD-L1 expression of 1% or greater (median, 13.7 vs. 9.1 months; HR, 0.64; 98.6% CI, 0.46 to 0.90; p = 0.001) and in the overall population (median, 12.7 vs. 10.7 months; HR, 0.78; 98.2% CI, 0.62 to 0.98; p = 0.01). The gene discussed is CD274; the disease is neoplasm.